Session Date Time Title Presenter Affiliation Country. Yoshiki Mikami. Duk-Soo Bae. Michael Quinn. Yutaka Kawakami. Robert L.

Size: px
Start display at page:

Download "Session Date Time Title Presenter Affiliation Country. Yoshiki Mikami. Duk-Soo Bae. Michael Quinn. Yutaka Kawakami. Robert L."

Transcription

1 Presidential Lecture Nov 30 16:20-16:50 Surgery for recurrent gynecologic cancer Ikuo Konishi President of ASGO, Professor Emeritus of Kyoto University Director of National Kyoto Medical Center, Kyoto, Educational Lecture Dec 01 10:20-11:20 Current concepts and controversies in gynecologic pathology Yoshiki Mikami Department of Diagnostic Pathology, Kumamoto University Hospital Invited Lecture 1 Nov 30 15:20-16:20 Translational model for precision medicine in gynecologic cancer Duk-Soo Bae Department of Obstetrics & Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Invited Lecture 1 Nov 30 15:20-16:20 Global teaching and training in gynaecological oncology Michael Quinn President of the International Gynaecological Cancer Society Australia Invited Lecture 2 Dec 01 10:20-11:20 Immunobiology and immunotherapy for gynecological cancers Yutaka Kawakami Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine Invited Lecture 2 Dec 01 10:20-11:20 NRG-GOG clinical trials group Robert L. Coleman University of Texas, M.D. Anderson Cancer Center, Houston, Texas USA Invited Lecture 3 Dec 02 12:20-13:30 Update on clear cell carcinoma of ovary Aikou Okamoto Department of Obstetrics and Gynecology, the Jikei University, School of Medicine Invited Lecture 3 Dec 02 12:20-13:30 Role of PARP inhibitors in ovarian cancer Mansoor-Raza Mirza Department of Oncology 5073 Rigshospitalet Copenhagen University Hospital Denmark

2 Invited Lecture 4 Dec 02 12:20-13:30 The biology of ovarian cancer Ernst Lengyel The Department of Obstetrics and Gynecology/Section of Gynecologic Oncology The University of Chicago, Chicago, Illinois, USA USA Invited Lecture 4 Dec 02 12:20-13:30 Sentinel navigation surgery for cervical cancer Fabrice Lécuru Gynecologic and Breast Oncologic Department, Georges Pompidou european Hospital, Paris, France. Medicine School. Paris Descartes University, Paris France France Educational Lecture Dec 01 10:20-11:20 Development of novel HPV therapeutic vaccine; mucosal immunotherapy of HPVtargeting therapy for treatment of highgrade CIN Kei Kawana Department of Obstetrics and Gynecology, Nihon University School of Medicine Morning Lecture 1 Dec 01 8:00-8:30 Treatment strategy for young women with ovarian cancer Kimio Ushijima Department of Obstetrics and Gynecology, Kurume University School of Medicine Morning Lecture 2 Dec 01 8:00-8:30 Role of robotic surgery in gynecologic cancer Suk-Joon Chang Division of Gynecologic Oncology Department of Obstetrics and Gynecology Ajou University School of Medicine

3 Symposium 1 Nov 30 13:10-15:00 Robotic surgery for gynecological cancers Masaki Mandai Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Sakyo-Ku, Kyoto, Symposium 1 Nov 30 13:10-15:00 Radical surgery for the pelvic side wall tumors in gynecologic cancers Hee-Seung Kim Seoul National University College of Medicine Symposium 1 Nov 30 13:10-15:00 Extensive surgery and robotic surgery for gynecologic oncology Kung-Liahng Wang Superintendent, Taitung Mackay Memorial Hospital, Taitung, Taiwan Professor, Dept of OBS and GYN, Mackay Medical College, Taipei, Taiwan President, Taiwan Association for Minimally Invasive Gynecology (TAMIG) President, Taiwanese Gynecologic Oncology Group (TGOG) Taiwan Symposium 1 Nov 30 13:10-15:00 Surgery for stage IIB cervical cancer role of radical surgery Mikio Mikami Tokai University, School of Medicine, Department of Obstetrics and Gynecology

4 Symposium 2 Nov 30 17:10-18:40 Precision gynecologic oncology in Taiwan Ting-Chang Chang Department of Obstetrics and Gynecology, Chang Gung Memorial Hospitals North Taiwan District Taiwan Symposium 2 Nov 30 17:10-18:40 Synthetic lethality in ovarian cancer Kousuke Yoshihara Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences Symposium 2 Nov 30 17:10-18:40 Molecular profiling and precision medicine in gynecologic cancer Katsutoshi Oda Department of Obstetrics and Gynecology, Faculty of Medicine, the University of Tokyo Symposium 2 Nov 30 17:10-18:40 Histology-specific expression of hox for a tailored chemoresistance-overcoming strategy in epithelial ovarian cancer: paclitaxel carboplatin does not fit all ovarian cancer any more. Dong-Hoon Suh Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Symposium 2 Nov 30 17:10-18:40 Deciphering intra-tumoral heterogeneity using molecular assessment of subtype heterogeneity to guide personalized medicine in ovarian cancer Ruby YunJu Huang Translational Centre for Development and Research of NUHS, Principal Investigator in CSI Singapore Singapore

5 Symposium 3 Dec 01 8:30-10:00 The future of robotic surgery for cervical cancer Fabrice Lécuru Department (Gynecologic and Breast Oncologic Surgery) Georges Pompidou European Hospital, Paris, France Head of Oncologic Pole, Georges Pompidou European Hospital, Paris, France France Symposium 3 Dec 01 8:30-10:00 Laparoscopic surgery for endometrial cancer in Yoshito Terai Obstetrics and Gynecology, Osaka Medical College Symposium 3 Dec 01 8:30-10:00 Feasibility of sentinel node navigation surgery in gynecological cancers Hitoshi Niikura Department of Gynecology, Tohoku University Hospital Symposium 3 Dec 01 8:30-10:00 Borderline ovarian tumours and fertility preservation Yin Nin Chia Gleneagles Hospital Singapore Singapore

6 Symposium 4 Dec 01 13:00-14:20 PD-1 signal inhibitors for gynecologic cancers: future perspectives Junzo Hamanishi The department of Obstetrics and Gynecology, Kyoto University, Symposium 4 Dec 01 13:00-14:20 Combination of therapeutic HPV dna vaccine with radiation and immune modulators in hpv associated tumor Sungjong Lee Department of Obstetrics and Gynecology, St. Vincent s Hospital, The Catholic University of, Suwon, Symposium 4 Dec 01 13:00-14:20 Immunologic profiles as potential biomarkers for predicting the outcome of ovarian cancer patients Yu-Li Chen Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan Taiwan Symposium 4 Dec 01 13:00-14:20 Reversal of immunosuppression in ovarian cancer microenvironment by targeting NFkB-IL6/IL8 signal and its clinical application Takashi Iwata Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Symposium 5 Dec 01 13:00-14:20 Cervical cancer screening in Hong Kong Yuen Sheung Hextan Ngan Department of obstetrics and gynaecology, the University of Hong Kong, Queen Mary Hospital, Hong Kong Hong Kong Symposium 5 Dec 01 13:00-14:20 Cervical cancer screening in Asia Neerja Bhatla Department of Obstetrics & Gynaecology All India Institute of Medical Sciences New Delhi, India India Symposium 5 Dec 01 13:00-14:20 Cervical cancer screening in Malaysia Suresh Kumarasamy Consultant Gynaecological Cncologist, Gleneagles Penang Malaysia Symposium 5 Dec 01 13:00-14:20 Cervical cancer screening in and its directed approach Masatsugu Ueda Vice President, Cytopathology and Gynecology, Osaka Center for Cancer and Cardiovascular Disease Prevention, Osaka,

7 Symposium 6 Dec 01 14:40-16:10 YAP silencing as a new therapeutic strategy for ovarian cancer Ju-Won Roh Department of Obstetrics & Gynecology, Dongguk University, Seoul, Symposium 6 Dec 01 14:40-16:10 Therapeutic strategy for ovarian clear cell carcinoma Seiji Mabuchi Osaka University Graduate School of Medicine (Dept of OBGYN), Symposium 6 Dec 01 14:40-16:10 Selection of antitumor drugs for ovarian cancer based on molecular and pathological subtypes. Noriomi Matsumura Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine Symposium 6 Dec 01 14:40-16:10 Pathology of serous tubal intraepithelial carcinoma (STIC) and high rade ovarian serous carcinoma Steven G. Silverberg University of Maryland School of Medicine Baltimore, MD, USA /USA Symposium 7 Dec 01 16:30-18:00 Pathogenic germline variants of ovarian, fallopian tube, and peritoneal cancers in ese Akira Hirasawa Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Symposium 7 Dec 01 16:30-18:00 The impact of hereditary features on the clinical management of peritoneal, ovarian and fallopian tube cancer Myong Cheol Lim Gynecologic Cancer Branch & Center for Uterine Cancer National Cancer Center Symposium 7 Dec 01 16:30-18:00 the gbrcam prevalence study and clinical management of hereditary ovarian cancer in china Xiaohua Wu Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center China Symposium 7 Dec 01 16:30-18:00 Taiwanese patients with ovarian cancer prevalence of BRCA1/2 germline and somatic mutations and its clinical implication Angel Chao Department of the Obstetrics and Gynecology of the Chang Gung Memorial Hospital, Linkou Medical Center. Taiwan

8 Fertility sparing surgery of trachelectomy for cervical cancer Hiroaki Kobayashi Department of of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University Outcomes of fertility-preserving high-dose progestin therapy for young patients with endometrial cancer Nobuyuki Susumu Department of Obstetrics and Gynecology, International University of Health and Welfare, Narita, Chiba, Fertility-sparing strategy for gynecologic cancers Jeong-Yeol Park M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Fertility preservation of endometrial cancer in China Jianliu Wang Vice President of Peking University People s Hospital. Chairman, Professor of Department of Obstetrics and Gynecology China A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: clinical oncology group study JCOG1203 Toyomi Satoh Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Symposium 9 Dec 02 9:30-11:00 Endometrial cancers an Indian experience Abraham Peedicayil Department of Gynaecologic Oncology CMC Hospital, INDIA India Symposium 9 Dec 02 9:30-11:00 Immunotherapy in endometrial cancer Jung-Yun Lee Yonsei University, Seoul, Symposium 9 Dec 02 9:30-11:00 Management of lymph nodes in endometrial cancer Yukiharu Todo Hokkaido Cancer Center, Division of Gynecologic Oncology Symposium 9 Dec 02 9:30-11:00 The recent novel findings in adjuvant chemotherapy for endometrial cancer Hiroyuki Nomura Department of Obstetrics and Gynecology, Keio University School of Medicine

ASGO The 4th International Workshop on Gynecologic Oncology

ASGO The 4th International Workshop on Gynecologic Oncology ASGO The 4th International Workshop on Gynecologic Oncology Program & Abstracts Date November 12 (Sat), 2016 Venue President Sendai International Center, Japan Nobuo YAEGASHI, M.D., Ph.D Soon-Beom Kang

More information

History of ASGO and International Collaboration. Kurume University, Kurume, Japan Toshiharu Kamura, MD, PhD.

History of ASGO and International Collaboration. Kurume University, Kurume, Japan Toshiharu Kamura, MD, PhD. History of ASGO and International Collaboration Kurume University, Kurume, Japan Toshiharu Kamura, MD, PhD. IGCS 2002 Seoul, Korea President Prof. Jung-Eun Mok In 1997, the 6 th IGCS was held in Japan,

More information

3 rd ASGO Workshop Overview Index... 77

3 rd ASGO Workshop Overview Index... 77 C O N T E N T S Welcome Message... 02 3 rd ASGO Workshop Overview... 03 ASGO Organizing Committee... 04 Program... 05 Official Sponsors... 07 Exhibition... 08 Day 1... 09 SESSION I New trends in the management

More information

2 nd JGO Editorial Board Meeting. Date & Time: 12 November 2016, 12:00~13:00PM Venue: 1F, Conference Building, Sendai Int l Center, Sendai

2 nd JGO Editorial Board Meeting. Date & Time: 12 November 2016, 12:00~13:00PM Venue: 1F, Conference Building, Sendai Int l Center, Sendai 2 nd JGO Editorial Board Meeting Date & Time: 12 November 2016, 12:00~13:00PM Venue: 1F, Conference Building, Sendai Int l Center, Sendai As of Nov. 2016 Special thanks to JGO editorial advisors Agenda

More information

Quality of life (QoL) in metastatic breast cancer patients with. maintenance paclitaxel plus gemcitabine (PG) chemotherapy:

Quality of life (QoL) in metastatic breast cancer patients with. maintenance paclitaxel plus gemcitabine (PG) chemotherapy: Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy

More information

Founding Editorial Board Meeting of the JGO. Date & Time: November 14 th (Sat) 2015, 6:30~7:30AM Venue: Crystal Ballroom (2F) Lotte Hotel, Seoul

Founding Editorial Board Meeting of the JGO. Date & Time: November 14 th (Sat) 2015, 6:30~7:30AM Venue: Crystal Ballroom (2F) Lotte Hotel, Seoul Founding Editorial Board Meeting of the JGO Date & Time: November 14 th (Sat) 2015, 6:30~7:30AM Venue: Crystal Ballroom (2F) Lotte Hotel, Seoul Objective of this meeting Share the current status of the

More information

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator

More information

Index : Bridging Asia to the World- A New Era for Psychiatric Treatment

Index : Bridging Asia to the World- A New Era for Psychiatric Treatment 1 Index : 2 3 Mood disorders President Tung-Ping Su Honorary president Shigeto Yamawaki Division of Psychiatry, Faculty of Medicine, National Yang-Ming University Department of Psychiatry and Neurosciences,

More information

International. Newsletter of the Japanese Gynecologic Oncology Group (JGOG) Table of Contents

International. Newsletter of the Japanese Gynecologic Oncology Group (JGOG) Table of Contents International 2012 Mar. No.6 Newsletter of the Japanese Gynecologic Oncology Group (JGOG) Table of Contents The Ovarian Cancer Committee: Research results and future trials that we expect --------Kazunori

More information

National Gynae-oncology Conference 2012

National Gynae-oncology Conference 2012 National 2nd Organised By: Unit Kuala Lumpur Hospital Unit Ampang Hospital 2nd National Highlights Cervical Cancer Management of locally advanced cervical cancer Nerve sparing radical hysterectomy Surgery

More information

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?

More information

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department

More information

Preoperative risk assessment for lymph node metastasis in endometrial cancer (PALME study) : results of a Korean Gynecologic Oncology Group study

Preoperative risk assessment for lymph node metastasis in endometrial cancer (PALME study) : results of a Korean Gynecologic Oncology Group study Preoperative risk assessment for lymph node metastasis in endometrial cancer (PALME study) : results of a Korean Gynecologic Oncology Group study Sokbom Kang, 1 Joo-Hyun Nam, 2 Duk-Soo Bae, 3 Jae-Weon

More information

Clinical statistics of gynecologic cancers in Japan

Clinical statistics of gynecologic cancers in Japan J Gynecol Oncol. 2017 Mar;28(2):e32 pissn 2005-0380 eissn 2005-0399 Review Article Clinical statistics of gynecologic cancers in Japan Wataru Yamagami, 1,7 Satoru Nagase, 2,7 Fumiaki Takahashi, 3 Kazuhiko

More information

Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404

Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404 23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

UNIVERSITY OF MINNESOTA

UNIVERSITY OF MINNESOTA Twin Cities Campus Department of Obstetrics, Gynecology and Women s Health Medical School Mayo Mail Code 395 420 Delaware Street SE Minneapolis, MN 55455 Office: 612-626-3111 Fax: 612-626-0665 Quarterly

More information

Index. B Bilateral salpingo-oophorectomy (BSO), 69

Index. B Bilateral salpingo-oophorectomy (BSO), 69 A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell

More information

receive adjuvant chemotherapy

receive adjuvant chemotherapy Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer

More information

Prevention, Diagnosis and Treatment of Gynecologic Cancers

Prevention, Diagnosis and Treatment of Gynecologic Cancers Prevention, Diagnosis and Treatment of Gynecologic Cancers Jubilee Brown MD and Pamela T. Soliman MD, MPH Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer

More information

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Gynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1

Gynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1 What is Gynecologic Cancer Gynecologic Cancers Marge Ramsdell RN, MN, OCN Madigan Army Medical Center Any cancer that starts in a woman s reproductive organs Each GYN cancer is unique 5 main types Cervical

More information

(WG Whitfield Growden, MD; DR Diane Redington, CRNP)

(WG Whitfield Growden, MD; DR Diane Redington, CRNP) 2795 Estates Drive Park City, UT 84060 TRANSCRIPT FOR VIDEO #4: D IAGNOSIS AND TREATMENT OF GYN CARCINOSARCOMA WITH DR. WHITFIELD GROWDEN Interview, Massachusetts General Hospital January 5, 2017 Produced

More information

Summary... 2 GYNAECOLOGICAL CANCER Niraparib in second-line treatment for platinum sensitive recurrant ovarian cancer... 3

Summary... 2 GYNAECOLOGICAL CANCER Niraparib in second-line treatment for platinum sensitive recurrant ovarian cancer... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GYNAECOLOGICAL CANCER... 3 Niraparib in second-line treatment for platinum sensitive recurrant ovarian cancer...

More information

17 th ESO-ESMO Masterclass in clinical Oncology

17 th ESO-ESMO Masterclass in clinical Oncology 17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated

More information

Report from ESGO 16 October 2009, Belgrade, Serbia

Report from ESGO 16 October 2009, Belgrade, Serbia Report from ESGO 16 October 2009, Belgrade, Serbia Interactive Index Prevention and early detection of gynaecological cancers Update on HPV vaccine efficacy and safety Treatment of cervical cancer Treatment

More information

Facing Gynecologic Surgery?

Facing Gynecologic Surgery? Facing Gynecologic Surgery? Domenico Vitobello, MD Domenico Vitobello is the medical director of the Gynecologic Unit at the Humanitas Clinical and Research Center since 2009. He has developed a comprehensive

More information

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is

More information

Global Breast Cancer Conference 2019 (GBCC 2019) with Annual Meeting of Korean Breast Cancer Society (KBCS)

Global Breast Cancer Conference 2019 (GBCC 2019) with Annual Meeting of Korean Breast Cancer Society (KBCS) It is our great honor to invite you to the Global Breast Cancer Conference 2019 (GBCC 2019), which will be held at Songdo ConvensiA in Incheon, Korea, from April 25 (Thu) to 27 (Sat), 2019. Hosted by the

More information

Stage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante

Stage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante Stage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical

More information

Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma

Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma ORIGINAL STUDY Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma Jeong-Yeol Park, MD, PhD, Dae-Yeon Kim, MD, PhD, Dae-Shik Suh, MD, PhD, Jong-Hyeok Kim, MD, PhD, Yong-Man

More information

In this Update, I report on the latest US

In this Update, I report on the latest US UPDATE Gynecologic cancer Jason D. Wright, MD Dr. Wright is Sol Goldman Associate Professor, Chief of Division of Gynecologic Oncology, Vice Chair of Academic Affairs, Department of Obstetrics and Gynecology,

More information

Peter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective

Peter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective 第 53 回日本癌治療学会学術集会 ASCO, ESMO, ECCO からの招聘演者と講演予定 Peter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective Ralf A. Stahel (President

More information

Paul Murray University of Birmingham

Paul Murray University of Birmingham Paul Murray University of Birmingham College of Medical and Dental Sciences The people of the Midlands have every reason to be supremely proud of this great centre of healing, of teaching and of research.

More information

Gynecologic Cancer. Cleveland Clinic Offers State-of-the-Art Cancer Care

Gynecologic Cancer. Cleveland Clinic Offers State-of-the-Art Cancer Care Gynecologic Cancer Cleveland Clinic experts tailor treatment to their patients needs, taking into account the type of cancer, the age of the individual, the degree to which the cancer has spread and the

More information

Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae

Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae Journal of Cancer Research and Clinical Oncology (2018) 144:845 854 https://doi.org/10.1007/s00432-018-2599-3 ORIGINAL ARTICLE CANCER RESEARCH Second primary colorectal cancer among endometrial cancer

More information

CURRICULUM VITAE. Department of Diagnostic Radiology F Bachelor of Medicine: , China Medical Collage, Taiwan.

CURRICULUM VITAE. Department of Diagnostic Radiology F Bachelor of Medicine: , China Medical Collage, Taiwan. CURRICULUM VITAE Name: Cheng, Yu Fan Sex: Male Birth Date: July 29, 1956 Citizenship: Chinese Office Address: Department of Diagnostic Radiology Kaohsiung Chang Gung Memorial Hospital 123, Ta Pei Road,

More information

Gynecological Cancers in Primary Care

Gynecological Cancers in Primary Care Gynecological Cancers in Primary Care Nora M. Lersch MSN CRNP AOCNP Division of Gynecological Oncology Objectives Identify the incidence of ovarian, cervical, vulvar and endometrial cancer Identify common

More information

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial

More information

The 1 st Congress of Asian Society of Cardiovascular Imaging

The 1 st Congress of Asian Society of Cardiovascular Imaging The 1 st Congress of Asian Society of Cardiovascular Imaging April 27 (Friday) ~ April 28 (Saturday), 2007 Asan Medical Center, Seoul, Korea Number of Participants : 545 Participants from 26 Countries

More information

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

Adjuvant Therapies in Endometrial Cancer. Emma Hudson Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial

More information

Endometrial Cancer. Incidence. Types 3/25/2019

Endometrial Cancer. Incidence. Types 3/25/2019 Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy

More information

Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference

Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference Jpn J Clin Oncol 2010;40(Supplement 1)i38 i43 doi:10.1093/jjco/hyq125

More information

Patologia Molecular del Carcinoma de Ovario

Patologia Molecular del Carcinoma de Ovario Curso de Patologia Molecular XXVI Congreso Nacional de la SEAP Cadiz Patologia Molecular del Carcinoma de Ovario Jaime Prat Barcelona Ovarian Epithelial Tumors WHO 1999 and 2003 Serous Mucinous Endometrioid

More information

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES

More information

Fast Facts: Ovarian Cancer

Fast Facts: Ovarian Cancer Fast Facts Fast Facts: Ovarian Cancer Christina Fotopoulou MD PhD Consultant Gynaecological Oncologist Queen Charlotte s and Chelsea Hospital London, UK Thomas J Herzog MD Professor of Obstetrics and Gynecology

More information

21 st COLPOSCOPY. Past, Present and Future COURSE. Cervical Cancer Screening

21 st COLPOSCOPY. Past, Present and Future COURSE. Cervical Cancer Screening 21 st COLPOSCOPY COURSE Cervical Cancer Screening Past, Present and Future To register please visit register.sccps.org For more information, please visit www.sccps.org.sg or email: secretariat@sccps.org

More information

Cancer research investment should shift from late stage treatment to early stage detection No!

Cancer research investment should shift from late stage treatment to early stage detection No! Cancer research investment should shift from late stage treatment to early stage detection No! KC Soo National Cancer Centre Singapore Duke-NUS Graduate Medical School 3 caveats 1. The primacy of cancer

More information

Why did all biomarker identification studies fail in endometriosis?

Why did all biomarker identification studies fail in endometriosis? Why did all biomarker identification studies fail in endometriosis? Sun-Wei Guo Shanghai OB/GYN Hospital Fudan University hoxa10@outlook.com Diagnosis of endometriosis Current gold standard: Laparoscopic

More information

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss

More information

Human Papillomavirus Type and Clinical Manifestation in Seven Cases of Large-cell Neuroendocrine Cervical Carcinoma

Human Papillomavirus Type and Clinical Manifestation in Seven Cases of Large-cell Neuroendocrine Cervical Carcinoma BRIEF COMMUNICATION Human Papillomavirus Type and Clinical Manifestation in Seven Cases of Large-cell Neuroendocrine Cervical Carcinoma Kung-Liahng Wang, 1,2,3 Tao-Yeuan Wang, 4 Yu-Chuen Huang, 5,8,9 Jerry

More information

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019 MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments

More information

Invitation from Chongqing, China.

Invitation from Chongqing, China. Invitation from Chongqing, China. Dear Colleagues, You are cordially invited to join us for the AAGL Regional Meeting on Minimally Invasive Gynecology, in Chongqing, China, April 18 20. 2014. With the

More information

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS HIV and AIDS Related Cancers DR GORDON AMBAYO UHS INTRODUCTION People with HIV/AIDS are at high risk for developing certain cancers, such as: Kaposi's sarcoma, non-hodgkin lymphoma, and cervical cancer.

More information

AHCC Trials Group. The Buzz. Contents. AHCC06 First Interim Analysis. Newsletter Oct AHCC Trials Group

AHCC Trials Group. The Buzz. Contents. AHCC06 First Interim Analysis. Newsletter Oct AHCC Trials Group AHCC Trials Group Contents Page 1 The Buzz The First Interim Analysis of the AHCC06 Page 2 Happenings AHCC06 Ancillary Study Published: The Experience of the AHCC Trials Group Investigators in Town Page

More information

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia Blake.gilks@vch.ca The USCAP requires that anyone in a position

More information

AOSpine Principles Symposium Daegu

AOSpine Principles Symposium Daegu KOREA Course program AOSpine Principles Symposium Daegu March 5, 2016 Daegu, South Korea AOSpine the leading global academic community for innovative education and research in spine care, inspiring lifelong

More information

Staging and Treatment Update for Gynecologic Malignancies

Staging and Treatment Update for Gynecologic Malignancies Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths

More information

Biomarker for Response and Resistance in Ovarian Cancer

Biomarker for Response and Resistance in Ovarian Cancer 2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center

More information

Carcinoma of the Fallopian Tube

Carcinoma of the Fallopian Tube 119 Carcinoma of the Fallopian Tube APM HEINTZ, F ODICINO, P MAISONNEUVE, U BELLER, JL BENEDET, WT CREASMAN, HYS NGAN and S PECORELLI STAGING Anatomy Primary site The Fallopian tube extends from the posterior

More information

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader: SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental

More information

ENYGO REPORT. Summary

ENYGO REPORT. Summary ENYGO REPORT Summary The first ENYGO Workshop on Fertility Sparing in Gynaecological Oncology was held at La Paz University Hospital in Madrid (Spain) from 27 to 28 January 2017. It was a very successful

More information

Welcome! Here s our agenda for today:

Welcome! Here s our agenda for today: Welcome! Here s our agenda for today: What is ovarian cancer? What causes it? When does genetic testing come in? When are families at risk for ovarian cancer? What are the treatments? 3 things to remember

More information

Lynparza. Lynparza (olaparib) Description

Lynparza. Lynparza (olaparib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)

More information

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous Note: If available, clinical trials should be considered as preferred treatment options for eligible patients (www.mdanderson.org/gynonctrials). Other co-morbidities are taken into consideration prior

More information

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center Ovarian cancer is not a single disease Ovarian Epithelial Tumors: Histological Spectrum* Type Frequency Histology High-Grade

More information

FERTILITY SPARING IN ENDOMETRIAL CANCER

FERTILITY SPARING IN ENDOMETRIAL CANCER FERTILITY SPARING IN ENDOMETRIAL CANCER Prof. Dr. Bülent Özçelik Erciyes University Medical Faculty Department of Obstetrics and Gynecology Gynecologic Oncology Unit Endometrial Cancer Most frequent gynecologic

More information

Evolving Treatment Strategies for Cervical Cancer

Evolving Treatment Strategies for Cervical Cancer Evolving Treatment Strategies for Cervical Cancer Nadeem Abu-Rustum, MD Memorial Sloan Kettering Cancer Center Evolving Treatment Strategies 1. Surgery 2. Radiation 3. Chemotherapy Incidence of cervix

More information

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

Gynecologic Malignancies. Kristen D Starbuck 4/20/18 Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial

More information

Practice of Medicine-1 Ovarian Cancer Clinical Correlation

Practice of Medicine-1 Ovarian Cancer Clinical Correlation Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by

More information

Topic. Speaker. Session. Detection. Buffet Lunch. Session Beginner to. Expert. Tea Break. Diseases

Topic. Speaker. Session. Detection. Buffet Lunch. Session Beginner to. Expert. Tea Break. Diseases 24 Feb 2017 (Fri) Lectures and n Venue: Cheung Kung Hai Lecturee Theatre, LKS Faculty of Medicine Co organized by Department of Medicine & Department of Surgery The University of Hong Kong & Queen Mary

More information

Trial record 1 of 1 for:

Trial record 1 of 1 for: Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,

More information

TITLE: Elucidation of Molecular Alterations in Precursor Lesions of Ovarian Serous Carcinoma

TITLE: Elucidation of Molecular Alterations in Precursor Lesions of Ovarian Serous Carcinoma AD Award Number: W81XWH-09-1-0249 TITLE: Elucidation of Molecular Alterations in Precursor Lesions of Ovarian Serous Carcinoma PRINCIPAL INVESTIGATOR: Robert Kurman, M.D. CONTRACTING ORGANIZATION: Johns

More information

TGH Annual Report (2016) Editorial Office

TGH Annual Report (2016) Editorial Office TGH Annual Report (2016) Editorial Office tgh@amegroups.com Outline of the Report 1.Basic Information 2.Editor-in-Chief 3.Message from the EIC 4.Distribution of Editorial Board Members 5.Number of Published

More information

OVARIAN CANCER CLINICAL TRIALS

OVARIAN CANCER CLINICAL TRIALS OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking

More information

Triage of Ovarian Masses. Andreas Obermair Brisbane

Triage of Ovarian Masses. Andreas Obermair Brisbane Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led

More information

Controversies in the Management of Advanced Ovarian Cancer

Controversies in the Management of Advanced Ovarian Cancer 안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking

More information

Raccomandazioni del Genetista. Dott.ssa Raffaella Casolino - Oncologia Negrar

Raccomandazioni del Genetista. Dott.ssa Raffaella Casolino - Oncologia Negrar Raccomandazioni del Genetista Dott.ssa Raffaella Casolino - Oncologia Negrar Genetic Test and Ovarian Cancer International Recomandations for BRCA Genetic Test NCCN (National Comprehensive Cancer Network):

More information

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch

More information

Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles

Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles 1 st SEUD Meeting, 9 May 2015, Paris, France Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles ENDOMETRIOSIS ovarian endometrioma

More information

From Research to Practice: What s New in Gynecologic Cancers?

From Research to Practice: What s New in Gynecologic Cancers? From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology

More information

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion 5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year

More information

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention 6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology

More information

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review

More information

Pr. Arnaud Wattiez Prof OBGYN University of strasbourg - France Head of GYN Department, Latifa Hospital, Dubai - UAE

Pr. Arnaud Wattiez Prof OBGYN University of strasbourg - France Head of GYN Department, Latifa Hospital, Dubai - UAE Dear Colleagues, On behalf of Presidents Dr. Muna Tahlak and Pr. Jacques Donnez, I am pleased to share with you an overview of Endo Dubai 2018. We hope that you can join us in Dubai and be part of this

More information

CONTENT. Singapore: Development of Traditional Chinese Medicinal Industry Attracts Attentions... 3

CONTENT. Singapore: Development of Traditional Chinese Medicinal Industry Attracts Attentions... 3 CONTENT Chinese Medicine in the World Japan to Formulate Guidelines on Chinese Medicinal Prescriptions... 3 Acupuncture Act Vetoed in Brazilian Senate... 3 Singapore: Development of Traditional Chinese

More information

Precision Therapies. for. Women s Cancers

Precision Therapies. for. Women s Cancers Precision Therapies for Women s Cancers 1 Company Snapshot Founded Q3 2016, a Delaware Incorporation Spin-out of Oncology Venture Aps, Denmark Seed of $3.5 million completed December, 2016 Focus: advancing

More information

Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group

Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial

More information

BRCA mutation carrier patient: How to manage?

BRCA mutation carrier patient: How to manage? BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE

More information

Michael Haake, M.D. CMC Main - LCI 1021 Morehead Medical Drive Charlotte, NC (980) Aug Aug. 1976

Michael Haake, M.D. CMC Main - LCI 1021 Morehead Medical Drive Charlotte, NC (980) Aug Aug. 1976 Michael Haake, M.D. Certifications Board Certified Radiation Oncology, May 1988. American Board of Radiology. Issued May 26, 1988. Internal Medicine. American Board of Internal Medicine, Certificate Number

More information

Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)

Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) ACOG District II 2 Learning Objectives At the end of this clinical presentation, obstetrician gynecologists and other women s health care

More information

Current Concept in Ovarian Carcinoma: Pathology Perspectives

Current Concept in Ovarian Carcinoma: Pathology Perspectives Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian

More information

Both type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be

Both type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be Recent studies have led to the development of a new paradigm for the pathogenesis and origin of EOC, based on a dualistic model of carcinogenesis that divides EOC into 2 broad categories designated types

More information

Background Management of high risk, early stage endometrial cancer is controversial. Historically, adjuvant pelvic radiation therapy is standard for

Background Management of high risk, early stage endometrial cancer is controversial. Historically, adjuvant pelvic radiation therapy is standard for A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-risk, Early-stage Endometrial Cancer: A Gynecology

More information

INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for

INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for more deaths than both cervical and endometrial tumours.

More information

Nomogram predicting risk of lymphocele in gynecologic cancer patients undergoing pelvic lymph node dissection

Nomogram predicting risk of lymphocele in gynecologic cancer patients undergoing pelvic lymph node dissection Original Article Obstet Gynecol Sci 2017;60(5):440-448 https://doi.org/10.5468/ogs.2017.60.5.440 pissn 2287-8572 eissn 2287-8580 Nomogram predicting risk of lymphocele in gynecologic cancer patients undergoing

More information

Hitting the High Points Gynecologic Oncology Review

Hitting the High Points Gynecologic Oncology Review Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and

More information

Epithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer?

Epithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer? Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer? Ann E. Smith Sehdev, MD Director, Center for Gynecologic Pathology Cascade Pathology, Portland, Oregon Ann E. Smith Sehdev has no

More information